NO20051473L - Behandling mot brekninger. - Google Patents

Behandling mot brekninger.

Info

Publication number
NO20051473L
NO20051473L NO20051473A NO20051473A NO20051473L NO 20051473 L NO20051473 L NO 20051473L NO 20051473 A NO20051473 A NO 20051473A NO 20051473 A NO20051473 A NO 20051473A NO 20051473 L NO20051473 L NO 20051473L
Authority
NO
Norway
Prior art keywords
albuterol
heaves
isomer
animals
vomiting
Prior art date
Application number
NO20051473A
Other languages
English (en)
Other versions
NO20051473D0 (no
Inventor
Vincent B Ciofalo
Original Assignee
Courage Corp Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Courage Corp Pty Ltd filed Critical Courage Corp Pty Ltd
Publication of NO20051473D0 publication Critical patent/NO20051473D0/no
Publication of NO20051473L publication Critical patent/NO20051473L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Soil Working Implements (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Fremgangsmåter og formuleringer er beskrevet for å forbedre helse og overlevelse hos dyr som lider av lufthiving og som omfatter å administrere den optisk rene R(-)-isomer av albuterol, mens det minimaliseres eller elimineres de uønskede aktiviteter av den tilsvarende S(+)-isomer av albuterol. Oppfinnelsen er også rettet mot en gunstig oral administrasjon av R(-)-albuterol til dyr og i matvareformuleringer for dyr som lider av lufthiving, og som omfatter den optisk aktive adrenergiske beta-reseptor-agonist R(-)albuterol.
NO20051473A 2003-07-24 2005-03-18 Behandling mot brekninger. NO20051473L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48986303P 2003-07-24 2003-07-24
US10/889,906 US20050020692A1 (en) 2003-07-24 2004-07-13 Treatment of heaves
PCT/US2004/022645 WO2005009426A1 (en) 2003-07-24 2004-07-14 Treatment of heaves

Publications (2)

Publication Number Publication Date
NO20051473D0 NO20051473D0 (no) 2005-03-18
NO20051473L true NO20051473L (no) 2006-02-20

Family

ID=34083599

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051473A NO20051473L (no) 2003-07-24 2005-03-18 Behandling mot brekninger.

Country Status (11)

Country Link
US (1) US20050020692A1 (no)
EP (1) EP1562568B1 (no)
JP (1) JP2006528628A (no)
AT (1) ATE418331T1 (no)
AU (1) AU2004258909B2 (no)
CA (1) CA2499307A1 (no)
DE (1) DE602004018607D1 (no)
NO (1) NO20051473L (no)
NZ (1) NZ539026A (no)
RU (1) RU2328279C2 (no)
WO (1) WO2005009426A1 (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7761533B2 (en) * 2005-09-21 2010-07-20 Sap Ag Standard implementation container interface for runtime processing of web services messages
NZ706573A (en) 2012-12-21 2019-11-29 Boehringer Ingelheim Vetmedica Gmbh Ciclesonide for the treatment of airway disease in horses
DE102014202366B4 (de) * 2014-02-10 2017-01-12 Voith Patent Gmbh Hydrodynamische Maschine, insbesondere hydrodynamischer Retarder
EP3157522B1 (en) * 2014-06-18 2019-09-04 Boehringer Ingelheim Vetmedica GmbH Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US5552442A (en) * 1987-09-15 1996-09-03 The Rowett Research Institute Therapeutic applications of clenbuterol
US5530029A (en) * 1987-09-15 1996-06-25 The Rowett Research Institute Therapeutic applications of clenbuterol
ES2085468T3 (es) * 1990-01-05 1996-06-01 Sepracor Inc Albuterol r(-) opticamente puro para tratar el asma.
US5362755A (en) * 1990-01-05 1994-11-08 Sepracor, Inc. Method for treating asthma using optically pure (R)-albuterol
US5442118A (en) * 1994-04-22 1995-08-15 Sepracor, Inc. Asymmetric synthesis of (R)- and (S)-arylethanolamines from iminoketones
US5545745A (en) * 1994-05-23 1996-08-13 Sepracor, Inc. Enantioselective preparation of optically pure albuterol
US5399765A (en) * 1994-05-23 1995-03-21 Sepracor, Inc. Enantioselective preparation of optically pure albuterol
US5708036A (en) * 1996-01-29 1998-01-13 Pesterfield, Jr.; E. Charles Method of treating premature uterine contractions using the optically active R(-)-isomer of albuterol
NZ500250A (en) * 1997-04-30 2001-03-30 Bridge Pharma Inc Adrenergic beta-2 agonist eutomers, feed compositions and use for increasing muscle and decreasing fat
US6951215B1 (en) * 2000-07-14 2005-10-04 Tufts University Drug delivery device for animals

Also Published As

Publication number Publication date
RU2328279C2 (ru) 2008-07-10
US20050020692A1 (en) 2005-01-27
AU2004258909B2 (en) 2008-03-13
EP1562568B1 (en) 2008-12-24
NO20051473D0 (no) 2005-03-18
ATE418331T1 (de) 2009-01-15
NZ539026A (en) 2007-10-26
DE602004018607D1 (de) 2009-02-05
CA2499307A1 (en) 2005-02-03
AU2004258909A1 (en) 2005-02-03
RU2005111988A (ru) 2006-01-20
EP1562568A1 (en) 2005-08-17
EP1562568A4 (en) 2005-08-31
JP2006528628A (ja) 2006-12-21
WO2005009426A1 (en) 2005-02-03

Similar Documents

Publication Publication Date Title
HK1112843A1 (en) Oral, quickly disintegrating film, which cannot be spit out, containing olanzapin
EP1673078A4 (en) BENZYL ETHER AND BENZYLAMINO BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
MY143795A (en) Tetrahydropyridoindole derivatives
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
UA74443C2 (uk) Ліганди 5-нт рецептора та їх використання
MXPA06011327A (es) Azaindoles utiles como inhibidores de jak y otras proteinas cinasas.
MXPA05012678A (es) Forma cristalina del agonista del receptor adrenergico beta2.
TW200633978A (en) 2,3,4,9-tetrahydro-1H-carbazole derivatives as crth2 receptor antagonists
MY147370A (en) Novel compounds and compositions and methods of use
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
TW200716204A (en) Pharmaceutical composition
SG151327A1 (en) Deazapurines useful as inhibitors of janus kinases
TW200630090A (en) Triazoles useful as inhibitors of protein kinases
SG165326A1 (en) Compositions and methods to counteract oral malodour
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
UA87494C2 (en) Azaindoles useful as inhibitors of jak and other protein kinases
TW200517107A (en) Novel formulation
SG165324A1 (en) Compositions and methods to counteract oral malodour
NO20051473L (no) Behandling mot brekninger.
DE60317935D1 (de) Alpha-aminoamid-derivate als mittel gegen migräne
NO20065471L (no) Anvendelse av IL-6 for behandling eller forebygging av kjemoterapiindusert nevropati.
MXPA05011699A (es) Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior.
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole
TW200509890A (en) Treatment of heaves
WO2004018436A3 (fr) Composes derives d'arylcarbamates, preparation et utilisations

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application